# Combined top 10 from each PICO category for non_small_cell_lung_NL_cleaned.json

## Population

1. (Patients, score 14) study, ten centres in the Netherlands participated. The STARS trial was performed in 28 sites in USA, China, and France. Both studies were closed early because of slow accrual. The number of included patients (n=58 patients) remained far below the anticipated enrolment (anticipated enrolment: 1030 patients in the STARS trial and 960 patients in the ROSEL trial). In these two trials, 31 patients were treated by stereotactic radiotherapy and 27 patients underwent surgery. Patients with peripherally located lesions received a total radiation dose of 54 Gy in three 18 Gy fractions. In patients with centr

2. (Patients, score 14) ds participated. The STARS trial was performed in 28 sites in USA, China, and France. Both studies were closed early because of slow accrual. The number of included patients (n=58 patients) remained far below the anticipated enrolment (anticipated enrolment: 1030 patients in the STARS trial and 960 patients in the ROSEL trial). In these two trials, 31 patients were treated by stereotactic radiotherapy and 27 patients underwent surgery. Patients with peripherally located lesions received a total radiation dose of 54 Gy in three 18 Gy fractions. In patients with central lesions, 50 Gy in four 12.5 Gy fr

3. (Patients, score 14) ites in USA, China, and France. Both studies were closed early because of slow accrual. The number of included patients (n=58 patients) remained far below the anticipated enrolment (anticipated enrolment: 1030 patients in the STARS trial and 960 patients in the ROSEL trial). In these two trials, 31 patients were treated by stereotactic radiotherapy and 27 patients underwent surgery. Patients with peripherally located lesions received a total radiation dose of 54 Gy in three 18 Gy fractions. In patients with central lesions, 50 Gy in four 12.5 Gy fractions was used. Treatment delivery was recommended t

4. (Patients, score 14) arly because of slow accrual. The number of included patients (n=58 patients) remained far below the anticipated enrolment (anticipated enrolment: 1030 patients in the STARS trial and 960 patients in the ROSEL trial). In these two trials, 31 patients were treated by stereotactic radiotherapy and 27 patients underwent surgery. Patients with peripherally located lesions received a total radiation dose of 54 Gy in three 18 Gy fractions. In patients with central lesions, 50 Gy in four 12.5 Gy fractions was used. Treatment delivery was recommended to be complete within 5 days of its initiation. A toxicity

5. (Patients, score 14) . The number of included patients (n=58 patients) remained far below the anticipated enrolment (anticipated enrolment: 1030 patients in the STARS trial and 960 patients in the ROSEL trial). In these two trials, 31 patients were treated by stereotactic radiotherapy and 27 patients underwent surgery. Patients with peripherally located lesions received a total radiation dose of 54 Gy in three 18 Gy fractions. In patients with central lesions, 50 Gy in four 12.5 Gy fractions was used. Treatment delivery was recommended to be complete within 5 days of its initiation. A toxicity risk-adapted fractional sche

6. (Population, score 13) BCP)
1. Overall survival
One study compared ABCP with BCP in a total of 800 nonsquamous NSCLC patients with an ECOG
performance-status score of 0 to 1 (Socinski, 2018). After a protocol amendment the primary endpoint overall
survival was reported in the 692 patients who had a wild-type genotype (WT population; patients with EGFR
or ALK genetic alterations were excluded). The percentage of patients alive at 1 year was 67.3% of the 356
patients in the ABCP group versus 60.6% of the 336 patients in the BCP group. The median survival was 19.2
months and 14.7 months, respectively. The HR for death was 0.78 (

7. (Population, score 13) erall surviva||l|
Row 3: One study compared ABCP with BCP in a total of 800 nonsquamous NSCLC patients with an ECOG performance-status score of 0 to 1 (Socinski, 2018). After a protocol amendment the primary endpoint overall survival was reported in the 692 patients who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded). The percentage of patients alive at 1 year was 67.3% of the 356 patients in the ABCP group versus 60.6% of the 336 patients in the BCP group. The median survival was 19.2 months and 14.7 months, respectively. The HR for death was 0.78 (

8. (Patients, score 13) patients), Nivolumab (2 studies with a total
of 2,280 patients); atezolizumab (1 study with a total 1,200 patients of whom 800 patients are used fort his
literature summary). One study (Hellmann, 2018) also assessed the effectivity and safety of Nivolumab plus
Ipilimumab. Socinski (2018) randomised patients into 3 groups, but only reported results of 2 groups. See
table 1 and evidence tables for details of the studies. All studies included patients of multiple hospitals across
different countries. The length of follow-up varied between a median of 4.2 months and 24 months. Only
patients with a baselin

9. (Patients, score 13) bevacizumab, carboplatin and
paclitaxel (BCP)
1. Overall survival
One study compared ABCP with BCP in a total of 800 nonsquamous NSCLC patients with an ECOG
performance-status score of 0 to 1 (Socinski, 2018). After a protocol amendment the primary endpoint overall
survival was reported in the 692 patients who had a wild-type genotype (WT population; patients with EGFR
or ALK genetic alterations were excluded). The percentage of patients alive at 1 year was 67.3% of the 356
patients in the ABCP group versus 60.6% of the 336 patients in the BCP group. The median survival was 19.2
months and 14.7 month

10. (Patients, score 13) all survival
One study compared ABCP with BCP in a total of 800 nonsquamous NSCLC patients with an ECOG
performance-status score of 0 to 1 (Socinski, 2018). After a protocol amendment the primary endpoint overall
survival was reported in the 692 patients who had a wild-type genotype (WT population; patients with EGFR
or ALK genetic alterations were excluded). The percentage of patients alive at 1 year was 67.3% of the 356
patients in the ABCP group versus 60.6% of the 336 patients in the BCP group. The median survival was 19.2
months and 14.7 months, respectively. The HR for death was 0.78 (95% CI 0.6

## Intervention

1. (Treatment, score 17) munotherapy in addition to neoadjuvant chemotherapy may have little to
no effect on health-related quality of life when compared to neoadjuvant chemotherapy
alone.
Very low
GRADE Source: Forde 2022, Felip 2022 [CheckMate 816]
Neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy (perioperative treatment)
Neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy may increase overall
survival* when compared to neoadjuvant chemotherapy alone.
Low
Source: Wakelee 2023 [KEYNOTE-671], Provencio 2023 [NADIM-II]*
GRADE
Neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy may increase event-
free su

2. (Intervention, score 13) ne immunotherapy with PD-1-, PD-L1- and CTLA4-inhibitors (with or without chemotherapy) in patients with non–small-cell lung cancer stage IIIB/IV without sensitizing and druggable oncogene driver mutations compared to platinum-based doublet chemotherapy?|
Row 13: |
Row 14: P (population)| Row 1: I (intervention)|immunotherapy with PD-1-, PD-L1- and CTLA4-inhibitors (with or without chemotherapy);
Row 2: C (comparison|) platinum-based doublet chemotherapy;
Row 3: |
Row 4: PDF aangemaakt op 23-01-2025 231/428|
Row 5: | Row 1: Niet kleincellig longcarcinoom
Row 2: 
Row 3: Z: p-value of overall effect; df: de

3. (Intervention, score 13) s (NEJ009 and the Beverly study) reported the effect of first generation TKI + other treatment versus first generation TKI on OS. Treatment with first generation TKI + other treatment resulted in a longer OS compared to treatment with first generation TKI. The absolute differences in OS between the intervention and control group was 5% in the NEJ009 trial after 5 years and 5% in the Beverly study after a median follow up of 36.3 months. The pooled HR is 0.79 (95%CI 0.64; 0.99) favoring treatment with first generation TKI+other treatment. This difference was not considered clinically relevant.||
Row 10: In

4. (Treatment, score 13) s: (Reck, 2016)
Treatment with pembrolizumab possibly results in a better quality of life compared to
treatment with chemotherapy in patients with advanced non-small-cell lung cancer and a
Low
PD-L1 tumor proportion score ≥50%.
GRADE
Reference: (Brahmer, 2017)
Pembrolizumab possibly results in less treatment-related adverse events compared with
chemotherapy in patients with advanced non-small-cell lung cancer and a PD-L1 tumor
Low
proportion score ≥50%.
GRADE
References: (Reck, 2016)
Pembrolizumab with chemotherapy (platinum-pemetrexed) versus placebo with chemotherapy (platinum-
pemetrexed)
Pembrolizu

5. (Treatment, score 13) 7) of the patients in the
pembrolizumab group plus chemotherapy versus 5.9% (n=12) in the chemotherapy group the adverse event
led to death.
99% adverse events occurred in the pembrolizumab combination group versus 97% in the chemotherapy
group (RR 1.01; 95% CI 0.99 to 1.02). 63.6% grade 3, 4, or 5 treatment-related adverse events adverse events
occurred in the pembrolizumab combination group versus 56.4% in the chemotherapy group (RR 1.14; 95%
CI 0.80 to 1.63) (Ghandi, 2018; Langer, 2016), see figure 4.
Figure 4 Safety (adverse events and toxicity) pembrolizumab plus chemotherapy versus chemotherapy
Z

6. (Treatment, score 13) tistical heterogeneity; CI: confidence interval
4. Quality of life
None of the included studies comparing ipilimumab plus chemotherapy with chemotherapy reported on
quality of life.
5. Safety (adverse events and toxicity)
Two studies comparing ipilimumab plus chemotherapy with chemotherapy reported treatment-related
adverse events (Govindan, 2017; Lynch, 2012) in a total of 952 patients. Approximately 95.4% of the patients
in the ipilimumab group versus 92.1% of the patients in the chemotherapy group had adverse events (RR
1.10; 95% CI 1.03 to 1.17), favouring chemotherapy (figure 7), however Lynch, 20

7. (Treatment, score 13) of events was
higher than the total number of patients. Grade 3, 4, or 5 treatment-related adverse events occurred in
approximately 54.2% of the patients in the ipilimumab group versus 41.3% in the chemotherapy group (RR
1.18; 95% CI 0.89 to 1.56) (Govindan, 2017; Lynch, 2012), see figure 8. Seven treatment-related deaths
occurred with chemotherapy plus ipilimumab, and one occurred with chemotherapy plus placebo.
Figure 8 Safety (adverse events and toxicity) ipilimumab plus chemotherapy versus chemotherapy
Z: p-value of overall effect; df: degrees of freedom; 2I: statistical heterogeneity; CI: confide

8. (Treatment, score 13) e chemotherapy.
Moderate
GRADE
Reference: (Huang, 2018)
Because of a lack of data, it was not possible to compare quality of life of pembrolizumab
with chemotherapy in patients with advanced non-small-cell lung cancer after first line
chemotherapy.
GRADE
Reference: (-)
Pembrolizumab results in less treatment-related adverse events compared with
chemotherapy in PD-L1 positive patients with advanced non-small-cell lung cancer after
Low
first line chemotherapy.
GRADE
Reference: (Huang, 2018)
Atezolizumab versus chemotherapy
Atezolizumab possibly results in a higher overall survival compared to chemotherap

9. (Treatment, score 13) ed quality of life when compared to neoadjuvant chemotherapy alone.|
Row 13: ||||||
Row 14: ||||||
Row 15: Very low GRADE||||||
Row 16: |||||Source: Forde 2022, Felip 2022 [CheckMate 816|
Row 17: ||||||
Row 18: ||||||
Row 19: Neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy (perioperative treatment||||||)
Row 20: |||||Neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy may increase overall survival* when compared to neoadjuvant chemotherapy alone.|
Row 21: ||||||
Row 22: |||||survival|
Row 23: ||||||
Row 24: ||||||
Row 25: ||Low||||
Row 26: |||||Source: Wakelee 2023 [KEYNOTE-671], Prov

10. (Treatment, score 13) y of life||||||
Row 13: None of the included studies comparing ipilimumab plus chemotherapy with chemotherapy reported on quality of life.||||||
Row 14: ||||||
Row 15: 5. Safety (adverse events and toxicity)||||||
Row 16: Two studies comparing ipilimumab plus chemotherapy with chemotherapy reported treatment-related adverse events (Govindan, 2017; Lynch, 2012) in a total of 952 patients. Approximately 95.4% of the patients in the ipilimumab group versus 92.1% of the patients in the chemotherapy group had adverse events (RR 1.10; 95% CI 1.03 to 1.17), favouring chemotherapy (figure 7), however Lynch, 20

## Comparator

1. (Placebo, score 5) L858R) na complete resectie en eventuele
adjuvante chemotherapie. In de ADAURA studie onderzocht men het effect van adjuvant osimertinib versus
placebo in deze setting. Deze studie liet klinische relevante voordelen zien: osimertinib verhoogt wellicht de
5-jaarsoverleving (85%) in vergelijking met placebo (73%) (Tsuboi, 2023) en resulteert wellicht in een
aanzienlijk langere ziektevrije overleving en betere CNS controle. Na 24 maanden was 89% van de patiënten
in leven en ziektevrij in de osimertinib groep, terwijl dit 52% was in de placebo groep (Wu, 2022). Op basis
van de studie van Majem (2022) co

2. (Placebo, score 5) n compared to placebo (73%).
Low
GRADE Sources: (Tsuboi, 2023)
Osimertinib may increase disease-free survival (median 68 months) when compared to
placebo (median 28 months).
Low
GRADE
Sources: (Wu, 2020; Herbst, 2023)
QoL may not be substantially different with adjuvant osimertinib when compared to
placebo.
Low
GRADE
Sources: (Majem, 2022)
The evidence suggests that osimertinib results in more patients (9 more per 100 treated
patients) with adverse events grade 3 or higher when compared to placebo.
Low
GRADE
Sources: (Wu, 2020; Herbst, 2023)
Other adjuvant treatments
No evidence is available regardin

3. (Placebo, score 5) and John (2023)). They evaluated the efficacy and safety of adjuvant osimertinib
versus placebo in patients with completely resected stage IB-IIIA (7th TNM classification) NSCLC harbouring
an EGFR-mutation. A total of 682 patients were randomized to receive osimertinib (n=339) (80 mg once daily)
or placebo (n=343) for 36 months. The median age (range) was 64 (30-86) in the osimertinib group compared
to 62 (31-82) in the placebo group. In the osimertinib group 108/339 (32%) were males, compared with
96/343 (28%) in the placebo group. The planned treatment duration of 3 years was completed by 66% of th

4. (Placebo, score 5) resected stage IB-IIIA (7th TNM classification) NSCLC harbouring
an EGFR-mutation. A total of 682 patients were randomized to receive osimertinib (n=339) (80 mg once daily)
or placebo (n=343) for 36 months. The median age (range) was 64 (30-86) in the osimertinib group compared
to 62 (31-82) in the placebo group. In the osimertinib group 108/339 (32%) were males, compared with
96/343 (28%) in the placebo group. The planned treatment duration of 3 years was completed by 66% of the
patients in the osimertinib group and 41% of the patients in the placebo group (Herbst, 2023). Cross-over was
not allowed.

5. (Placebo, score 5) tients were randomized to receive osimertinib (n=339) (80 mg once daily)
or placebo (n=343) for 36 months. The median age (range) was 64 (30-86) in the osimertinib group compared
to 62 (31-82) in the placebo group. In the osimertinib group 108/339 (32%) were males, compared with
96/343 (28%) in the placebo group. The planned treatment duration of 3 years was completed by 66% of the
patients in the osimertinib group and 41% of the patients in the placebo group (Herbst, 2023). Cross-over was
not allowed. The following relevant outcomes were reported: OS (secondary end point), DFS (primary end
point), A

6. (Placebo, score 5) eived placebo (RR 0.74 (95% CI 0.38 to 1.43)).
Treatment related adverse events were only reported at the first data cut-off point with a median follow-up of
14.5 months. Treatment related adverse events of any grade occurred in 322 (67.8%) patients in the
durvalumab group versus 125 (53.4%) in the placebo group (RR 1.27 (95% CI 1.11 to 1.45)). Treatment related
grade 3 or 4 adverse events occurred in 56 (11.8%) patients in the durvalumab group versus 10 (4.4%) in the
placebo group (RR 2.76 (95% CI 1.43 to 5.31)).
Level of evidence comparison durvalumab versus placebo
There are four levels of evidenc

7. (Placebo, score 5) 1.08)).
Treatment related adverse events of any grade occurred in 353 (34%) patients in the tecemotide group versus
129 (27%) in the placebo group (RR 1.27 (95% CI 1.08 to 1.51)). Treatment related grade 3 or 4 adverse
events occurred in 15 (1%) patients in the tecemotide group versus 5 (1%) in the placebo group (RR 1.40 (95%
CI 0.51 to 3.82)).
Adverse events leading to death occurred in 46 patients (4%) who received tecemotide and in 35 patients
(7%) who received placebo (RR 0.61 (95% CI 0.40, 0.94)).
Level of evidence comparison tecemotide versus placebo
There are four levels of evidence: high, mod

8. (Placebo, score 5) L858R) na complete resectie en eventuele adjuvante chemotherapie. In de ADAURA studie onderzocht men het effect van adjuvant osimertinib versus placebo in deze setting. Deze studie liet klinische relevante voordelen zien: osimertinib verhoogt wellicht de 5-jaarsoverleving (85%) in vergelijking met placebo (73%) (Tsuboi, 2023) en resulteert wellicht in een aanzienlijk langere ziektevrije overleving en betere CNS controle. Na 24 maanden was 89% van de patiënten in leven en ziektevrij in de osimertinib groep, terwijl dit 52% was in de placebo groep (Wu, 2022). Op basis van de studie van Majem (2022) co

9. (Placebo, score 5) Row 12: Treatment related adverse events of any grade occurred in 353 (34%) patients in the tecemotide group versus 129 (27%) in the placebo group (RR 1.27 (95% CI 1.08 to 1.51)). Treatment related grade 3 or 4 adverse events occurred in 15 (1%) patients in the tecemotide group versus 5 (1%) in the placebo group (RR 1.40 (95% CI 0.51 to 3.82)).||
Row 13: ||
Row 14: Adverse events leading to death occurred in 46 patients (4%) who received tecemotide and in 35 patients (7%) who received placebo (RR 0.61 (95% CI 0.40, 0.94)).||
Row 15: ||
Row 16: Level of evidence comparison tecemotide versus placebo||

10. (Placebo, score 5) rain metastases.|Afatinib|Gefitinib
Row 10: |||40 mg daily.|250 mg daily.
Row 11: Paz-Ares, 2017)|||n=160|
Row 12: |controlled trial|||n=159
Row 13: ||||
Row 14: ||||
Row 15: ||||
Row 16: 1st generation TKI + other treatment versus 1st generation TKI||||
Row 17: RELAY study (Nakagawa,|Double-blind, placebo- controlled, phase 3 trial|Untreated, metastatic, EGFR mutated NSCLC patients.|Erlotinib 150 mg/day AND Ramucirumab 10 mg/kg once every 2 weeks|Placebo once every 2 weeks AND erlotinib 15 mg/day
Row 18: 2019,||||
Row 19: Yoh, 2020,||||
Row 20: Nadal, 2022)||||
Row 21: ||||
Row 22: |||n=224|n= 225
R

## Outcome

1. (Safety, score 18) erapy);
O (outcome) overall survival, progression free survival, response rate, quality of life, safety;
Relevant outcome measures
The working group considered overall survival a critical outcome measure for the decision-making process;
and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important
outcome measures for decision making.
The working group defined clinically relevant differences as follows:
Overall survival: Benefit >12 weeks or hazard ratio <0.7
Progression free survival: Benefit >12 weeks or hazard ratio <0.7
Adverse events and toxicity:

2. (Safety, score 17) rvival, progression free survival, response rate, quality of life, safety (adverse events
and toxicity).
Relevant outcome measures
The working group considered overall survival a critical outcome measure for the decision making process;
and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important
outcome measures for decision making.
The working group report clinically relevant outcomes as follows:
Overall survival: Benefit >12 weeks or hazard ratio < 0.7.
Progression free survival: Benefit > 12 weeks or hazard ratio < 0.7.
Adverse events and toxicity

3. (Outcome, score 16) on free survival, response rate, quality of life, safety;
Relevant outcome measures
The working group considered overall survival a critical outcome measure for the decision-making process;
and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important
outcome measures for decision making.
The working group defined clinically relevant differences as follows:
Overall survival: Benefit >12 weeks or hazard ratio <0.7
Progression free survival: Benefit >12 weeks or hazard ratio <0.7
Adverse events and toxicity: lethal <5% (absolute difference), acute or seve

4. (Safety, score 16) rvival, progression free survival, response rate, quality of life, safety (adverse events
and toxicity).
Relevant outcome measures
The working group considered overall survival a critical outcome measure for the decision making process;
and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important
outcome measures for decision making.
The working group defined clinically relevant differences as follows:
Overall survival: >12 weeks or hazard ratio <0.7.
Progression free survival: >12 weeks or hazard ratio <0.7.
Adverse events and toxicity: lethal <5%, a

5. (Safety, score 16) val, progression free survival, response rate, quality of life, safety;|||
Row 6: ||||
Row 7: Relevant outcome measures||||
Row 8: The working group considered overall survival a critical outcome measure for the decision-making process; and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important outcome measures for decision making.||||
Row 9: ||||
Row 10: The working group defined clinically relevant differences as follows:||||
Row 11: ||||
Row 12: Overall survival||: Benefit >12 weeks or hazard ratio <0.7||
Row 13: Progression free survival|||: Ben

6. (Outcome, score 15) e, quality of life, safety (adverse events
and toxicity).
Relevant outcome measures
The working group considered overall survival a critical outcome measure for the decision making process;
and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important
outcome measures for decision making.
The working group report clinically relevant outcomes as follows:
Overall survival: Benefit >12 weeks or hazard ratio < 0.7.
Progression free survival: Benefit > 12 weeks or hazard ratio < 0.7.
Adverse events and toxicity: lethal < 5% (absolute difference), acute or se

7. (Outcome, score 15) e, quality of life, safety (adverse events
and toxicity).
Relevant outcome measures
The working group considered overall survival a critical outcome measure for the decision making process;
and progression free survival, response rate, quality of life, safety (adverse events and toxicity) important
outcome measures for decision making.
The working group defined clinically relevant differences as follows:
Overall survival: >12 weeks or hazard ratio <0.7.
Progression free survival: >12 weeks or hazard ratio <0.7.
Adverse events and toxicity: lethal <5%, acute or severe <25%.
Response rate: No relevant

8. (Outcome, score 15) 21 days, or pemetrexed 500 mg/m2 day 1 every 21 days). The study reported the
following outcomes: overall survival (OS), progression free survival (PFS), overall response rate (ORR), and
adverse events (AEs). The median duration of follow-up was 3.4 months.
Study results
Overall survival - Critical outcome
Two of the two included studies reported on overall survival (OS).
De Langen (2023) reported the effect of sotorasib versus docetaxel on OS as secondary endpoint. The study
was not powered for OS. Treatment with sotorasib resulted in similar OS compared to treatment with
docetaxel (HR 1.01; 95% CI:

9. (Outcome, score 15) of ALK);
Row 2: O:Outcomes) =| Row 1: |||
Row 2: Relevant outcome measures|||
Row 3: The guideline development group considered overall survival as a critical outcome measure for decision making; and progression free survival, objective response rate, quality of life, adverse events as an important outcome measure for decision making.|||
Row 4: |||
Row 5: The working group defined clinically relevant differences based on the PASKWIL criteria (https://www.nvmo.org):|||
Row 6: (https://www.nvmo.org|||
Row 7: If median overall survival in control group ≤12 months:|||
Row 8: |||
Row 9: |Overall survival:

10. (Outcome, score 15) g/m2 day 1 every 21 days). The study reported the following outcomes: overall survival (OS), progression free survival (PFS), overall response rate (ORR), and adverse events (AEs). The median duration of follow-up was 3.4 months.||
Row 3: ||
Row 4: Study results||
Row 5: Overall survival - Critical outcome||
Row 6: Two of the two included studies reported on overall survival (OS).||
Row 7: ||
Row 8: De Langen (2023) reported the effect of sotorasib versus docetaxel on OS as secondary endpoint. The study was not powered for OS. Treatment with sotorasib resulted in similar OS compared to treatment with

